A new publication was released on August 13, 2026, in the journal Pharmaceuticals (Basel, Switzerland). The paper, titled "Radix Bupleuri Chinensis Extract Ameliorates Doxorubicin-Induced Spermatogenic Dysfunction: Involvement of the GnRHR Signaling Pathway and Taurine Biosynthesis," examines the GnRHR signaling pathway, which is relevant to compounds such as cetrorelix that act on gonadotropin-releasing hormone receptors.
The publication was indexed under PubMed ID 42653776. This is a factual record of the publication's release and journal placement. No findings, conclusions, or efficacy data from the study are summarized here.
Cetrorelix remains an approved compound, and this publication is noted for its relevance to GnRHR pathway research rather than as evidence about cetrorelix itself. Readers interested in the details of the study are encouraged to consult the original source directly.
For more background on cetrorelix, including its approved uses and mechanism, readers can consult the compound overview.